SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients SPRING HOUSE, Pa., Dec. 02, 2020 (GLOBE NEWSWIRE) -- SteroTherapeutics, LLC, a biopharmaceutical company developing new treatments for patients with rare diseases announced today the signing of a...

SteroTherapeutics Receives New U.S. Patent for treatment of non-alcoholic Steatohepatitis (NASH) PHILADELPHIA, March 28, 2019 (GLOBE NEWSWIRE) -- SteroTherapeutics, a privately held biopharmaceutical company developing therapies for metabolic diseases focused on non-alcoholic steatohepatitis...

SteroTherapeutics Receives FDA Orphan-Drug Designation PHILADELPHIA, April 04, 2018 (GLOBE NEWSWIRE) -- SteroTherapeutics, a privately held biopharmaceutical company developing therapies focused on metabolic diseases including non-alcoholic...

SteroTherapeutics Announces Closing of Financing to Accelerate Clinical Study for Non-Alcoholic Steatohepatitis (NASH) PHILADELPHIA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- SteroTherapeutics, a privately held biopharmaceutical company developing metabolic-based therapies focused on non-alcoholic steatohepatitis (NASH),...